Polarispharma: Polaris Group Announces Treatment of First Patient in a Phase 2 Study of ADI-PEG 20 Plus Gemcitabine and Docetaxel for Soft Tissue Sarcoma
SAN DIEGO, May 30, 2018 /PRNewswire/ -- Polaris Group announced today that the first patient has been dosed in a phase 2 trial of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatmread more
Read full article »
CEO
Steve J.P. Hsu
Polaris is a California-based biotechnology company that develops and commercializes novel anti-cancer therapies for the treatment of cancer.
Read more